Clinical Trial Update: A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC [Phase 3]

View source ↗

Summary

Phase 3 study update evaluating SHR-1210 in combination with pemetrexed and carboplatin for non-squamous non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED